Clinical Trial

JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma

Name: JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma — clinical trial record (NCT07336823)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory multiple myeloma. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY232 injection in the treatment of relapsed/refractory multiple myeloma.

Trial Details

NCT Number	NCT07336823
Lead Sponsor	Shenzhen Genocury Biotech Co., Ltd.
Conditions	Multiple Myeloma
Enrollment	9 participants
Start Date	2026-01-20
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-13